PBYI
Puma Biotechnology, Inc. Health Care Pharmaceutical Preparations Russell 3000
$10.44Close
$526.3MMarket cap
$4.73 – $11.2652-week range
Nov 5, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 94 · stronger than 94% of stocks over 12 months
- Earnings growing EPS +33% year on year, faster than the quarter before (+257 pts)
Cautions
- Results soon Nov 5, 2026, in 4 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
7%
1wk
down 5.3%
price change
1mo
up 5.1%
price change
12-month return
up 91%
market up 11% ·
its own up 91%
F-score
8 / 9
Exceptional
Altman Z
-2.56
Elevated risk
P/E
16.9×
price / earnings
PEG
—
P/E / EPS growth
P/B
4.0×
price / book
Earnings yield
up 7.5%
EBIT / enterprise value
Cheaper than
69%
of the market · cheap
Revenue growth
down 1%
year on year
EPS growth
up 33%
latest quarter · +257 pts
Sales growth
up 8%
latest quarter · +10 pts
ROE
up 28%
return on equity
Free cash margin
up 18%
$41.7M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
-0.6×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- issued more shares
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Long-term debt down 100% ($0.0B → $0.0B)
- Gross margin 72.1% → 74.5%
Trade setup
ATR%
4.1%
$0.43 a day · 2×ATR $9.58
RS
94 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.0×
vs 50-day average
Up/down volume
1.22
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Shareholders diluted The share count rose 2.7% over the year, from 49m to 50m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 0.9% over the year, from $230.5M to $228.4M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+11% vs market2 sessions after results
Financials
- Gross 75%
- Net 14%
- Free cash 18%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $225.1M | $253.2M | $228.0M | $235.6M | $230.5M | $228.4M |
| Gross margin | 83% | 75% | 76% | 73% | 72% | 75% |
| Operating income | -$30.4M | $1.3M | $23.7M | $32.6M | $31.0M | $37.3M |
| Net income | -$60.0M | $29.1M | $2,000 | $21.6M | $30.3M | $31.1M |
| Net margin | -27% | 12% | 0% | 9% | 13% | 14% |
| Earnings per share | -$1.52 | $0.72 | $0.00 | $0.45 | $0.62 | $0.61 |
| Free cash flow | $727,000 | $20.6M | -$15.8M | $26.9M | $38.9M | $41.7M |
| Free cash margin | 0% | 8% | -7% | 11% | 17% | 18% |
| Cash | $85.3M | $63.1M | $76.2M | $84.6M | $69.2M | $29.6M |
| Long-term debt | $84.0M | $97.1M | $98.3M | $65.7M | $21.7M | $0 |
| Shareholders' equity | -$6.0M | -$2.4M | $21.6M | $53.4M | $92.1M | $130.3M |
| Shares outstanding | 40.09m | 41.18m | 46.35m | 47.65m | 49.11m | 50.41m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 1, 2024 | Quarterly ↗ | Jun 30, 2024 | 32d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 6, 2026 | Results ↗ |
| Jun 16, 2026 | Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Feb 26, 2026 | Results ↗ |
| Nov 6, 2025 | Results ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 24, 2025 | Charter or bylaws ↗ |
| Jun 13, 2025 | Shareholder vote ↗ |
| May 9, 2025 | Director or officer change ↗ |
| May 8, 2025 | Results ↗ |
| Feb 27, 2025 | Results ↗ |
| Nov 7, 2024 | Results ↗ |